糖尿病黄斑水肿患者房水细胞因子水平与玻璃体腔注射雷珠单抗解剖学应答的关系
这项前瞻性多中心队列研究纳入49例伴中心型糖尿病黄斑水肿且黄斑中心亚区厚度≥310 μm的糖尿病患者,每月注射雷珠单抗0.5 mg共3个月,检测基线及2个月房水细胞因子,分析其与3个月解剖学应答的关系。结果显示基线房水ICAM-1升高与黄斑体积缩小相关,基线VEGF升高与黄斑体积增加及黄斑中心亚区厚度应答者 odds 降低相关。
要点
- 基线房水ICAM-1每增加100 pg/mL,3个月黄斑体积减少0.0379 mm³(P=.01)。
- 基线房水VEGF每增加100 pg/mL,3个月黄斑体积增加0.0731 mm³(P=.02)。
- 基线房水VEGF升高与黄斑中心亚区厚度应答者 odds 降低相关(OR 0.868,95%CI 0.755-0.998)。
核心结论
- 基线房水ICAM-1升高和VEGF降低与糖尿病黄斑水肿对雷珠单抗的有利解剖学应答相关,但解剖学应答与视力应答并不总是直接相关。
研究设计与样本
- 前瞻性多中心队列研究,2011年12月22日至2013年6月13日招募49例伴中心型糖尿病黄斑水肿、光谱域光学相干断层扫描黄斑中心亚区厚度≥310 μm的糖尿病患者,48例完成随访。
- 参与者每月注射雷珠单抗0.5 mg共3个月,基线和2个月时采集房水,用多重免疫分析法(双份检测)测定VEGF、胎盘生长因子、转化生长因子β2、ICAM-1、IL-6、IL-8、IL-10、血管细胞间黏附分子和单核细胞趋化蛋白1。
- 统计分析于2017年3月1日至2017年6月1日进行。
主要发现
- 48例参与者平均(SD)年龄61.9(7.1)岁,36例(75.0%)为男性。
- 第2个月较基线降低的细胞因子包括:ICAM-1中位变化-190.88(IQR -634.20至-26.54,P<.001)、VEGF中位变化-639.45(IQR -1040.61至-502.61,P<.001)、胎盘生长因子中位变化-1.31(IQR -5.99至-0.01,P<.001)、IL-6中位变化-38.61(IQR -166.72至-2.80,P<.001)、单核细胞趋化蛋白1中位变化-90.13(IQR -382.74至109.47,P=.01)。
- 控制年龄、中心凹无血管区大小和视网膜病变严重程度后,多元线性回归显示基线房水ICAM-1每增加100 pg/mL与3个月SD-OCT黄斑体积减少0.0379 mm³相关(P=.01)。
- 基线房水VEGF每增加100 pg/mL与3个月SD-OCT黄斑体积增加0.0731 mm³相关(P=.02),并与黄斑中心亚区厚度应答者 odds 降低相关(OR 0.868,95%CI 0.755-0.998)。
关键数值与推荐
- 纳入标准为中心型糖尿病黄斑水肿且光谱域光学相干断层扫描黄斑中心亚区厚度≥310 μm。
- 主要结局为基线和2个月房水细胞因子水平变化、3个月SD-OCT黄斑中心亚区厚度和黄斑体积变化,以及基线房水细胞因子与解剖学应答的统计学关联。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Variability in response to anti-vascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME) remains a significant clinical challenge. Biomarkers could help anticipate responses to anti-VEGF therapy. OBJECTIVES: To investigate aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of DME, and to determine the association between baseline aqueous levels and anatomic response. DESIGN, SETTING, AND PARTICIPANTS: In this prospective multicenter cohort study, 49 participants with diabetes mellitus complicated by center-involving DME, with a central subfield thickness of 310 μm or greater on spectral-domain optical coherence tomography (SD-OCT), were recruited from December 22, 2011, to June 13, 2013 and statistical analysis were performed from March 1, 2017, to June 1, 2017. A total of 48 participants proceeded to follow-up. INTERVENTIONS: Participants received monthly injections of ranibizumab, 0.5 mg, for 3 months. Aqueous fluid for cytokine analysis was obtained at baseline and repeated at the 2-month visit. Multiplex immunoassay was carried out in duplicate for VEGF, placental growth factor, transforming growth factor beta 2, intercellular adhesion molecule 1 (ICAM-1), interleukin 6 (IL-6), IL-8, IL-10, vascular intercellular adhesion molecule, and monocyte chemoattractant protein 1. MAIN OUTCOMES AND MEASURES: Baseline and 2-month change in aqueous cytokine levels, 3-month change in SD-OCT central subfield thickness and macular volume (MV), and the statistical association between baseline aqueous cytokine levels and these measures of anatomic response to ranibizumab in center-involving DME. RESULTS: Among the 48 participants, the mean (SD) age was 61.9 (7.1) years and 36 participants (75.0%) were men. The following cytokines were lower at month 2 vs baseline: ICAM-1 (median change, -190.88; interquartile range [IQR], -634.20 to -26.54; P < .001), VEGF (median change, -639.45; IQR, -1040.61 to -502.61; P < .001), placental growth factor (median change, -1.31; IQR, -5.99 to -0.01; P < .001), IL-6 (median change, -38.61; IQR, -166.72 to -2.80; P < .001), and monocyte chemoattractant protein 1 (median change, -90.13; IQR, -382.74 to 109.47; P = .01). When controlling for age, foveal avascular zone size, and severity of retinopathy, multiple linear regression determined that increasing baseline aqueous ICAM-1 was associated with a favorable anatomic response, in terms of reduced SD-OCT MV at 3 months (every additional 100 pg/mL of baseline ICAM-1 was associated with a reduction of 0.0379 mm3; P = .01). Conversely, increasing baseline aqueous VEGF was associated with a less favorable SD-OCT MV response at 3 months (every additional 100 pg/mL of baseline VEGF was associated with an increase of 0.0731 mm3; P = .02) and was associated with lower odds of being a central subfield thickness responder (odds ratio, 0.868; 95% CI, 0.755-0.998). CONCLUSIONS AND RELEVANCE: Elevated aqueous ICAM-1 and reduced VEGF levels at baseline are associated with a favorable anatomic response to ranibizumab in DME, although there is not always direct correlation between anatomic and visual acuity response.
引用
- Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. 2018. PMID: 29522144. doi:10.1001/jamaophthalmol.2018.0179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。